Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...

Appropriate use of immune checkpoint inhibitors and immunotherapy differs in adults with unresectable, metastatic cutaneous ...

Desmoda (desmopressin acetate) Vasopressin 2 receptor agonist Management of central diabetes insipidus as antidiuretic replacement therapy for adults and pediatric patients. FDA Approves Desmoda Oral ...

Clinical utility may be greatest with careful patient selection, given frailty-associated toxicity and potential endpoint inflation in indolent tumors, warranting larger validation cohorts and ...

Ipsen receives CHMP’s positive opinion on Ojemda for treating monotherapy of children with relapsed or refractory BRAF-altered paediatric low-grade glioma: Paris Wednesday, Marc ...

February 2026 proved to be a pivotal month for the oncology landscape, as the FDA green-lit several therapies targeting some ...

Researchers found that combining trametinib, rigosertib, and a CD40 agonist blocked immune-suppressive B cells and restored anti-PD-1 response in resistant melanoma models. The strategy could expand ...

Cancer begins when mutations in specific genes override the body’s built-in controls on cell division, allowing rogue cells ...

(OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 25 February 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company ...

PRAME franchise Phase 1/2 data to be presented in 2H 2026: brenetafusp in ovarian and lung cancer, and initial data with half-life extended candidate (IMC-P115C) Additional Phase 1 HIV data to be ...

KIMMTRAK (tebentafusp-tebn) Q4 net sales of $104.5 million and $400.0 million for full year 2025; expect moderating revenue growth in 2026 TEBE-AM enrollment completion anticipated 1H 2026 with ...